Please login to the form below

Aplidin

This page shows the latest Aplidin news and features for those working in and with pharma, biotech and healthcare.

abaloparatide) and confirming its earlier rejection of Pharma Mar’s Aplidin (plitidepsin) as a treatment for multiple myeloma.

Promising new agents for multiple myeloma

Other anti-cancer agents. Plitidepsin (Aplidin; PharmaMar) induces cell death through various cellular pathways.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Group Account Director, Healthcare Brand Communications, London: Excellent Package

No results were found

Add my company

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...